Overview

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Status:
RECRUITING

Trial end date:
2030-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cyclophosphamide
Decitabine
Dexamethasone
fludarabine